There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – Research Report), Eli Lilly & Co (LLY – Research Report) and Abbott Labs (ABT – Research Report) with bullish sentiments.
Mineralys Therapeutics, Inc. (MLYS)
Bank of America Securities analyst Greg Harrison reiterated a Buy rating on Mineralys Therapeutics, Inc. yesterday and set a price target of $39.00. The company’s shares closed last Monday at $12.50.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mineralys Therapeutics, Inc. with a $38.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Eli Lilly & Co (LLY)
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on Eli Lilly & Co, with a price target of $500.00. The company’s shares closed last Monday at $454.08, close to its 52-week high of $469.87.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $510.03 average price target, implying a 12.5% upside from current levels. In a report issued on July 26, Citi also maintained a Buy rating on the stock with a $525.00 price target.
Abbott Labs (ABT)
In a report released yesterday, Air Ma from Citi reiterated a Buy rating on Abbott Labs, with a price target of $130.00. The company’s shares closed last Monday at $108.45.
Currently, the analyst consensus on Abbott Labs is a Moderate Buy with an average price target of $123.56, which is a 14.4% upside from current levels. In a report issued on July 23, Barclays also assigned a Buy rating to the stock with a $132.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MLYS:
- Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- MLYS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
- Mineralys expands lorundrostat trial and with inhibitor combo for CKD treatment
- Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
